cAMP-specific 3',5'-cyclic phosphodiesterase (cAMP-PDE)

cAMP-hydrolyzing phosphodiesterases (PDEs) are a group of enzymes that regulate intracellular signaling by catalyzing the hydrolysis of cyclic adenosine monophosphate (cAMP) into 5'-AMP. This group primarily includes the cAMP-specific families (PDE4, PDE7, and PDE8) and dual-specificity families (PDE1, PDE2, PDE3, PDE10, and PDE11) that also act on cGMP. By controlling cAMP levels, these enzymes modulate the activity of protein kinase A (PKA) and EPAC, which in turn regulate diverse processes such as inflammation, smooth muscle contraction, and cardiac function. The PDE4 family, for instance, consists of four genes (PDE4A-D) that produce numerous isoforms through alternative splicing, each with distinct tissue distributions and regulatory properties. PDE4 is the most prominent cAMP-hydrolyzing isoform in immune cells and has been successfully targeted for the treatment of inflammatory diseases like COPD, psoriasis, and atopic dermatitis. PDE3 is another key cAMP-hydrolyzing enzyme, primarily targeted in cardiovascular conditions to improve cardiac output and blood flow. Therapeutic inhibition of these isoforms increases intracellular cAMP, leading to anti-inflammatory effects and relaxation of smooth muscle. However, the development of these drugs is often limited by side effects, most notably gastrointestinal distress and emesis, which are associated with the inhibition of specific isoforms like PDE4D in the central nervous system and gut.

Other names

cAMP-hydrolyzing phosphodiesterasecAMP-specific phosphodiesterasecAMP-PDEPDE4PDE7PDE8PDE3

Inhibition of the phosphodiesterase enzyme, preventing the hydrolysis of cAMP to 5'-AMP, thereby increasing intracellular cAMP levels and activating PKA and EPAC signaling pathways.